ArticleBioinformatics (Oxford, England)2024
Accurate and transferable drug-target interaction prediction with DrugLAMP.
Article in Bioinformatics (Oxford, England), 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
12 citing papers in PubMed.
- Multiscale cross modal fusion and cascaded signal propagation for drug target interaction prediction.iScience · 2026Article
- DMAPLM: A multimodal pretrained framework for computational drug repositioning.PLoS computational biology · 2026Article
- Large language models for bioinformatics.Quantitative biology (Beijing, China) · 2026Review
- One-hot news: drug synergy models shortcut molecular features.Bioinformatics (Oxford, England) · 2026Article
- Deciphering DEL pocket patterns through contrastive learning.Nature communications · 2026Article
- PLXFPred: interpretable cross-attention networks with hierarchical fusion of multi-modal features for predicting protein-ligand interactions and affinities.Bioinformatics (Oxford, England) · 2026Article
- Multimodal pre-training models of molecular representation for drug discovery.National science review · 2026Review
- LNMGAT: a laplacian regularized pseudo-negative mining graph attention network for robust drug-target interaction prediction under multi-scenario cold-start settings.Frontiers in bioinformatics · 2026Article
- CAMF-DTI: Enhancing Drug-Target Interaction Prediction via Coordinate Attention and Multi-Scale Feature Fusion.Current issues in molecular biology · 2025Article
- A survey on deep learning for drug-target binding prediction: models, benchmarks, evaluation, and case studies.Briefings in bioinformatics · 2025Review
- Top-DTI: integrating topological deep learning and large language models for drug-target interaction prediction.Bioinformatics (Oxford, England) · 2025Article
- Artificial intelligence in traditional Chinese medicine: advances in multi-metabolite multi-target interaction modeling.Frontiers in pharmacology · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
Abstract
motivationAccurate prediction of drug-target interactions (DTIs), especially for novel targets or drugs, is crucial for accelerating drug discovery. Recent advances in pretrained language models (PLMs) and multi-modal learning present new opportunities to enhance DTI prediction by leveraging vast unlabeled molecular data and integrating complementary information from multiple modalities.
resultsWe introduce DrugLAMP (PLM-assisted multi-modal prediction), a PLM-based multi-modal framework for accurate and transferable DTI prediction. DrugLAMP integrates molecular graph and protein sequence features extracted by PLMs and traditional feature extractors. We introduce two novel multi-modal fusion modules: (i) pocket-guided co-attention (PGCA), which uses protein pocket information to guide the attention mechanism on drug features, and (ii) paired multi-modal attention (PMMA), which enables effective cross-modal interactions between drug and protein features. These modules work together to enhance the model's ability to capture complex drug-protein interactions. Moreover, the contrastive compound-protein pre-training (2C2P) module enhances the model's generalization to real-world scenarios by aligning features across modalities and conditions. Comprehensive experiments demonstrate DrugLAMP's state-of-the-art performance on both standard benchmarks and challenging settings simulating real-world drug discovery, where test drugs/targets are unseen during training. Visualizations of attention maps and application to predict cryptic pockets and drug side effects further showcase DrugLAMP's strong interpretability and generalizability. Ablation studies confirm the contributions of the proposed modules. AVAILABILITY AND IMPLEMENTATION: Source code and datasets are freely available at https://github.com/Lzcstan/DrugLAMP. All data originate from public sources.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.